Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis, and Candida glabrata

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis, and Candida glabrata, Lead author: CG Carvalhaes presented at 10th Trends in Medical Mycology (TIMM10), October 8-11, Virtual and Abdereen, Scotland, UK.
Poster # 338

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. by Castanheira M, Doyle TB, Deshpande LM, Mendes RE and Sader HS. published in Int. J. Antimicrob. Agents. 2021; 58 (5): 106439

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020)

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020), Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program, Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL
Poster #36440

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Meropenem-Vaborbactam In Vitro Activities against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers in 2020

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Meropenem-Vaborbactam In Vitro Activities against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers in 2020 presented, Lead author: HS Sader. Presented at American Thoracic Society (ATS) 2021, May 14-19, Virtual Conference
Poster #8470

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. by Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS and Castanheira M published in J. Antimicrob. Chemother. 2021; 76 (11): 2833-2838

Minocycline activity against unusual clinically significant Gram-negative pathogens

Minocycline activity against unusual clinically significant Gram-negative pathogens. by Shortridge D, Arends SJR, Streit JM and Castanheira M. published in Antimicrob. Agents Chemother.
2021; 65 (11): e01264

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: Results from the SENTRY Antimicrobial Surveillance Program (2016-19).

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: Results from the SENTRY Antimicrobial Surveillance Program (2016-19). by Sader HS, Streit JM, Carvalhaes CG, Huband MD, Shortridge D, Mendes RE and Castanheira M. published in JAC – Antimicrob. Resist. 2021; dlab117

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents.

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. by Sader HS, Mendes RE, Doyle TB, Davis AP and Castanheira M. JAC Antimicrob. Resist. 2021; 3 (3): dlab136

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients.

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. by Sader HS, Duncan LR, Doyle TB and Castanheira M. published in JAC Antimicrob. Resist. 2021; 3 (3): dlab126

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against a Recent Collection of Fastidious Organisms Recovered from Respiratory Tract Infections

In vitro Activity of Tebipenem against a Recent Collection of Fastidious Organisms Recovered from Respiratory Tract Infections. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Five-Year Trends on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016-2020)

Five-Year Trends on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-2020)

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary ESBL-Producing and CRE Isolates, Including Isolates Producing Metallo-β-Lactamases

The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary ESBL-Producing and CRE Isolates, Including Isolates Producing Metallo-β-Lactamases. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States

Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftibuten-Avibactam against Clinical Isolates of Enterobacterales Producing Clinically Relevant Beta-Lactamases

Antimicrobial Activity of Ceftibuten-Avibactam against Clinical Isolates of Enterobacterales Producing Clinically Relevant Beta-Lactamases. Lead author: HS SAder presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020. Lead author: LR Duncan presented at IDWeek 2021 September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020)

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020)

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020)

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia. Lead author: D Shortridge presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020)

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020)

Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Epidemiology and Susceptibility Profiles of ST131-025b Escherichia coli Detected Among Cephalosporin- and/or Carbapenem-Resistant Isolates Collected in United States Hospitals

Epidemiology and Susceptibility Profiles of ST131-025b Escherichia coli Detected Among Cephalosporin- and/or Carbapenem-Resistant Isolates Collected in United States Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Optimization of a 96-Well Plate Format Assay to Evaluate Concentration-Dependent Activity of a Monoclonal Antibody against the O Antigen 025b from ST131-H30 Escherichia coli

Optimization of a 96-Well Plate Format Assay to Evaluate Concentration-Dependent Activity of a Monoclonal Antibody against the O Antigen 025b from ST131-H30 Escherichia coli. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020)

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020)

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-Ocrtober 3, Virtual Conference

Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and In Vitro Activity of Tebipenem, Including against Strain Lineage and Resistant Subsets (2018-2020)

Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and In Vitro Activity of Tebipenem, Including against Strain Lineage and Resistant Subsets (2018-2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019)

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals. Lead author: D Shortridge, presented at IDWeek 2021, September 29-October 3, Virtual Conferece

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19)

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). by Shortridge D, Carvalhaes C, Deshpande L and Castanheira M. published in J Antimicrob Chemother. 2021; 76 (10): 2600-2605

Antimicrobial Susceptibility of Gram-negative Organisms from Southeast Asia

Antimicrobial Susceptibility of Gram-negative Organisms from Southeast Asia. Lead author: H Sader presented at 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), September 9-10, 2021, Virtual Conference
Poster #0323

Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019

Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019. by Huang DB, Sader HS, Rhomberg PR, Gaukel E and Borroto-Esoda K. published in Diagn. Microbiol. Infect. Dis. 2021; 101 (3): 115471

Antifungal drugs work together to treat germs causing fungal infections

Antifungal drugs work together to treat germs causing fungal infections. by Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA and Castanheira M. published in Future Microbiol. 2021; 16: 765-768

Intermethod Comparability Analyses of Gepotidacin Antimicrobial Susceptibility Tests Using Over 3,600 Globally-collected Clinical Isolates

Intermethod Comparability Analyses of Gepotidacin Antimicrobial Susceptibility Tests Using Over 3,600 Globally-collected Clinical Isolates. Lead author: SJR Arends presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Current Epidemiology and Activity of Gepotidacin and Comparator Agents Against Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in the Unites States

Current Epidemiology and Activity of Gepotidacin and Comparator Agents Against Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in the Unites States. Lead author: RE Mendes presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Extended-spectrum beta-lactamases: An update on their characteristics, epidemiology and detection.

Extended-spectrum beta-lactamases: An update on their characteristics, epidemiology and detection. by Castanheira M, Simner PJ and Bradford PA publised in JAC Antimicrob. Resist. 2021; 3 (3): dlab092

In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020)

In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020). Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1529

Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme.

Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme. by Carvalhaes CG, Rhomberg PR, Pfaller M and Castanheira M. published in JAC Antimicrob. Resist. 2021; 3 (2): dlab088